Neurokinin B/NK3 receptors exert feedback inhibition on l-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease

Neuropharmacology

Volumn 54, Issue 7, 2008, Pages 1143-1152

  Zhang, Xiaoqun ^a   Andren, Per E ^b   Chergui, Karima ^a   Svenningsson, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Basal ganglia; Dopamine; Parkinsonism; Striatum; Tachykinins

Indexed keywords

BENSERAZIDE; LEVODOPA; N (ALPHA ETHYLBENZYL) 3 METHYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; NEUROKININ 3 RECEPTOR; OXIDOPAMINE; SENKTIDE; SUBSTANCE P; TYROSINE 3 MONOOXYGENASE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; COCAINE; DOPAMINE; DRUG DERIVATIVE; PEPTIDE FRAGMENT; PROTEIN KINASE (CALCIUM,CALMODULIN) II; QUINOLINE DERIVATIVE; RADIOISOTOPE; SERINE;

AMPEROMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; EVOKED RESPONSE; HEMISPHERE; NEGATIVE FEEDBACK; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; SUBSTANTIA NIGRA; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; HEMISPHERIC DOMINANCE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPARKINSON AGENTS; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; COCAINE; DISEASE MODELS, ANIMAL; DOPAMINE; FEEDBACK; FUNCTIONAL LATERALITY; GENE EXPRESSION REGULATION; LEVODOPA; OXIDOPAMINE; PARKINSON DISEASE; PEPTIDE FRAGMENTS; QUINOLINES; RADIOISOTOPES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROKININ-3; SERINE; SUBSTANCE P; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 42749093115     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.03.005     Document Type: Article

References (48)

1. Berke J.D., Paletzki R.F., Aronson G.J., Hyman S.E., and Gerfen C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. J. Neurosci. 18 (1998) 5301-5310
2. Bonner T.I., Affolter H.U., Young A.C., and Young III W.S. A cDNA encoding the precursor of the rat neuropeptide, neurokinin B. Brain Res. 388 (1987) 243-249
3. Burgunder J.M., and Young III W.S. Distribution, projection and dopaminergic regulation of the neurokinin B mRNA-containing neurons of the rat caudate-putamen. Neuroscience 32 (1989) 323-335
4. Carter M.S., and Krause J.E. Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma. J. Neurosci. 10 (1990) 2203-2214
5. Cenci M.A. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends Neurosci. 30 (2007) 236-243
6. Chen L.W., Guan Z.L., and Ding Y.Q. Mesencephalic dopaminergic neurons expressing neuromedin K receptor (NK3): a double immunocytochemical study in the rat. Brain Res. 780 (1998) 150-154
7. Chergui K., Svenningsson P., and Greengard P. Physiological role for casein kinase 1 in glutamatergic synaptic transmission. J. Neurosci. 25 (2005) 6601-6609
8. Cotzias G.C. l-Dopa for Parkinsonism. N. Engl. J. Med. 278 (1968) 630
9. 3H] senktide. Brain Res. 506 (1990) 175-179
10. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
11. Dawson, L.A., Cato, K.J., Scott, C., Watson, J.M., Wood, M.D., Foxton, R., de la Flor, R., Jones, G.A., Kew, J.N., Cluderay, J.E., Southam, E., Murkitt, G.S., Gartlon, J., Pemberton, D.J., Jones, D.N., Davies, C.H., Hagan, J. In vitro and in vivo characterization of the non-peptide NK(3) receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology, in press.
12. Elliott P.J., Mason G.S., Stephens-Smith M., and Hagan R.M. Behavioural and biochemical responses following activation of midbrain dopamine pathways by receptor selective neurokinin agonists. Neuropeptides 19 (1991) 119-126
13. Engber T.M., Susel Z., Kuo S., Gerfen C.R., and Chase T.N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552 (1991) 113-118
14. Fukuhara S., Mukai H., Kako K., Nakayama K., and Munekata E. Further identification of neurokinin receptor types and mechanisms of calcium signaling evoked by neurokinins in the murine neuroblastoma C1300 cell line. J. Neurochem. 67 (1996) 1282-1292
15. Furuta T., Mori T., Lee T., and Kaneko T. Third group of neostriatofugal neurons: neurokinin B-producing neurons that send axons predominantly to the substantia innominata. J. Comp. Neurol. 426 (2000) 279-296
16. Furuta T., Koyano K., Tomioka R., Yanagawa Y., and Kaneko T. GABAergic basal forebrain neurons that express receptor for neurokinin B and send axons to the cerebral cortex. J. Comp. Neurol. 473 (2004) 43-58
17. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma Jr. F.J., and Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
18. Gerfen C.R., Miyachi S., Paletzki R., and Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 22 (2002) 5042-5054
19. Haycock J.W., Ahn N.G., Cobb M.H., and Krebs E.G. ERK1 and ERK2, two microtubule-associated protein 2 kinases, mediate the phosphorylation of tyrosine hydroxylase at serine-31 in situ. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 2365-2369
20. Henry B., Crossman A.R., and Brotchie J.M. Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 155 (1999) 204-220
21. Jocham G., Lezoch K., Muller C.P., Kart-Teke E., Huston J.P., and de Souza Silva M.A. Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core. Eur. J. Neurosci. 24 (2006) 1721-1732
22. Johnson K.D., Kim S.I., and Bresnick E.H. Differential sensitivities of transcription factor target genes underlie cell type-specific gene expression profiles. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 15939-15944
23. Johnston T.H., Lee J., Gomez-Ramirez J., Fox S.H., and Brotchie J.M. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Exp. Neurol. 191 (2005) 243-250
24. Krause J.E., Chirgwin J.M., Carter M.S., Xu Z.S., and Hershey A.D. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 881-885
25. Langlois X., Wintmolders C., te Riele P., Leysen J.E., and Jurzak M. Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 40 (2001) 242-253
26. Le Moine C., and Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comp. Neurol. 355 (1995) 418-426
27. Lucas L.R., and Harlan R.E. Cholinergic regulation of tachykinin- and enkephalin-gene expression in the rat striatum. Brain Res. Mol. Brain Res. 30 (1995) 181-195
28. Marco N., Thirion A., Mons G., Bougault I., Le Fur G., Soubrie P., and Steinberg R. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32 (1998) 481-488
29. Marksteiner J., Lassmann H., Saria A., Humpel C., Meyer D.K., and Sperk G. Neuropeptide levels after pentylenetetrazol kindling in the rat. Eur. J. Neurosci. 2 (1990) 98-103
30. Marksteiner J., Wahler R., Bellmann R., Ortler M., Krause J.E., and Sperk G. Limbic seizures cause pronounced changes in the expression of neurokinin B in the hippocampus of the rat. Neuroscience 49 (1992) 383-395
31. Nakanishi S. Mammalian tachykinin receptors. Annu. Rev. Neurosci. 14 (1991) 123-136
32. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzalo N., and Olanow C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23 (2000) S8-S19
33. Pavon N., Martin A.B., Mendialdua A., and Moratalla R. ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 59 (2006) 64-74
34. 2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J. Neurosci. 24 (2004) 5283-5291
35. 3 receptors. Eur. J. Pharmacol. 269 (1994) 73-78
36. Preston Z., Richardson P.J., Pinnock R.D., and Lee K. NK-3 receptors are expressed on mouse striatal gamma-aminobutyric acid-ergic interneurones and evoke [(3)H] gamma-aminobutyric acid release. Neurosci. Lett. 284 (2000) 89-92
37. Sarau H.M., Griswold D.E., Bush B., Potts W., Sandhu P., Lundberg D., Foley J.J., Schmidt D.B., Webb E.F., Martin L.D., Legos J.J., Whitmore R.G., Barone F.C., Medhurst A.D., Luttmann M.A., Giardina G.A., and Hay D.W. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. J. Pharmacol. Exp. Ther. 295 (2000) 373-381
38. Schapira A.H., Bezard E., Brotchie J., Calon F., Collingridge G.L., Ferger B., Hengerer B., Hirsch E., Jenner P., Le Novere N., Obeso J.A., Schwarzschild M.A., Spampinato U., and Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 5 (2006) 845-854
39. Shughrue P.J., Lane M.V., and Merchenthaler I. In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J. Comp. Neurol. 372 (1996) 395-414
40. Sivam S.P., and Krause J.E. Tachykinin systems in the spinal cord and basal ganglia: influence of neonatal capsaicin treatment or dopaminergic intervention on levels of peptides, substance P-encoding mRNAs, and substance P receptor mRNA. J. Neurochem. 59 (1992) 2278-2284
41. Sonomura T., Nakamura K., Furuta T., Hioki H., Nishi A., Yamanaka A., Uemura M., and Kaneko T. Expression of D1 but not D2 dopamine receptors in striatal neurons producing neurokinin B in rats. Eur. J. Neurosci. 26 (2007) 3093-3103
42. Spooren W., Riemer C., and Meltzer H. Opinion: NK3 receptor antagonists: the next generation of antipsychotics?. Nat. Rev. Drug Discov. 4 (2005) 967-975
43. Stoessl A.J., Szczutkowski E., Glenn B., and Watson I. Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Res. 565 (1991) 254-262
44. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 4350-4354
45. Whitty C.J., Paul M.A., and Bannon M.J. Neurokinin receptor mRNA localization in human midbrain dopamine neurons. J. Comp. Neurol. 382 (1997) 394-400
46. 2+-, calmodulin-dependent protein kinase. Purification and characterization. J. Biol. Chem. 256 (1981) 5404-5409
47. Zeng B.Y., Jolkkonen J., Jenner P., and Marsden C.D. Chronic l-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience 66 (1995) 19-28
48. Zhang X., Andren P.E., and Svenningsson P. Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Res. 1095 (2006) 207-210